Looking to beat the heat in the Twin Cities? Here's a list of cooling centers around the metro
WCCO has issued a NEXT Weather Alert for Sunday due to the dangerous heat, as well as the risk for severe storms.
For those looking for a place to stay cool, there are options.
The following places have cooling centers open across the Twin Cities for free during business hours:
For a complete list of cooling centers open in Hennepin County, click here. Minneapolis also has several free pools, beaches and splash pads to help people beat the heat.
To see a map of all the cooling centers and beaches in Ramsey County, click here.
To stay cool, experts encourage people to limit time in direct sunlight and drink plenty of water.
If you're going to be outside in the heat, doctors encourage wearing loose, light clothing and seeking shade when you can. It's recommended that anyone working or exercising in the elements drink at least one cup of water for every 20 minutes.
Older adults, young kids and anyone with underlying conditions are at greater risk from extreme heat.
In Minnesota, the number of heat-related hospitalizations spikes at a feels-like temperature of only 86 degrees.
Cramps, rapid pulse and dizziness are early signs to watch out for when it comes to heat-related illness. Adam Del Rosso and
Aki Nace
contributed to this report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
3 minutes ago
- CBS News
A little more sunshine expected across Maryland Thursday
A thick blanket of clouds hung over Maryland as moisture streamed northward Wednesday afternoon. While most of the steady rain stayed in southern Maryland, a few stray showers did manage to pop up during the afternoon. Skies will manage to clear late tonight, some patchy fog could develop-especially in low-lying river valleys. Overnight lows will fall into the 60s for most, with some cooler spots in the upper 50s in western Maryland. Looking ahead to Thursday and Friday, high pressure nearby will keep our weather relatively quiet. Winds coming in off the water will help hold temperatures a bit below normal for early August. Expect highs in the upper 70s to low 80s both days, with overnight lows in the upper 50s and 60s. We'll see a mix of clouds and sun Thursday-though clouds may win out by the afternoon. Friday is looking brighter overall, with a little more sun breaking through as the system overhead moves out. Rain chances look very limited to end the week, though we can't completely rule out a quick popup shower Thursday afternoon. If you are headed to the Ravens Pre-Season Game at the Bank Thursday evening, expect temps in the 70s under partly cloudy skies. Ideal weather for some football. As we head into the weekend, dry conditions are expected to continue across much of Maryland, along with slightly cooler-than-normal temperatures. Expect highs in the 80s with lows in the 60s. It will be warmer than it was during the week Next week brings some changes. Warmer air will start to push in from the south, leading to a slow return of humidity-and eventually, better chances for showers and storms. Monday and Tuesday could bring a few spotty, heat-driven showers. But the best chance for more widespread rain looks to arrive around midweek. By then, expect the humidity to return in full force. Heat index values could approach 100 degrees by Wednesday or Thursday, marking a noticeable shift from this week's cooler, cloudier pattern. In the meantime, enjoy the fresh air and mild temperatures-it's a break from the usual August heat, and it won't last much longer.
Wall Street Journal
17 minutes ago
- Wall Street Journal
RFK Jr., Vaccines and the Trial Bar
The plaintiffs bar has few restraints on its legal marauding on business and government, and now it's about to dismantle a rare oasis of legal sanity. That's the no-fault Vaccine Injury Compensation Program, which is being targeted by the trial bar's agent in the Trump Administration, Robert F. Kennedy Jr. 'The VICP has devolved into a morass of inefficiency, favoritism, and outright corruption,' Mr. Kennedy tweeted last week. He means that the program makes it harder for his trial lawyer friends to shake down vaccine makers. Congress established the VICP in 1986 as a flood of lawsuits were driving manufacturers out of the market. The program established special vaccine courts to review evidence and arbitrate claims. Patients are compensated from a trust fund, which is financed by a 75 cent excise tax on every vaccine sold. They have three years from their injury onset to bring claims. And they can automatically receive compensation for certain conditions that the government has linked to vaccines if their symptoms develop within a specified period of receiving a shot—for example, seven to 42 days for chronic arthritis for vaccines containing the rubella virus.
Medscape
28 minutes ago
- Medscape
FDA Approves Drug for Aggressive Glioma
The FDA has granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals) for H3 K27M-mutant diffuse glioma, marking the first time a systemic therapy has been approved for the aggressive glioma subtype. H3 K27M-mutant diffuse glioma is a grade 4 midline tumor that primarily affects children and young adults. Median survival is about a year. Historically, treatment has been limited to radiation, with few options available after recurrence besides palliative care. Dordaviprone is a first-in-class oral imipridone that disrupts tumor cell metabolism and increases tumor susceptibility to immune-mediated attack. Jazz Pharmaceuticals bought Chimerix in early 2025 for almost $1 billion based on dordaviprone's commercial prospects. 'Dordaviprone has the potential to rapidly become a standard of care for a rare oncology disease and also contribute durable revenue beginning in the near-term,' Jazz CEO Bruce Cozadd, said in a press release at the time. Approval was based on a pooled analysis of five single-arm studies enrolling 46 adults and four children with recurrent tumors previously treated with radiation, according to a statement from the FDA. Adults received 625 mg once weekly while pediatric patients received lower, weight-adjusted weekly doses. Mutation status was confirmed by immunohistochemistry or sequencing of archival tumor tissue. The overall response rate was 22%. The median time to response was 8.3 months, and the median duration of response (DOR) was 10.3 months. Among 11 patients with objective responses, 73% had a DOR of at least 6 months, and 27% had a DOR of at least 12 months. Seven of 15 evaluable patients (46.7%) were able to have corticosteroid dose reductions of at least 50%, and performance status improved in six of 34 (20.6%) patients. Sixty percent of subjects experienced treatment-related, treatment-emergent adverse events (TR-TEAEs), including fatigue (34%), nausea (18%), decreased lymphocyte levels (14%). The most common serious adverse events were hydrocephalus (8%) and nausea (8%). Grade 3 TR-TEAEs occurred in 20%, most commonly fatigue (10%). One case each of seizure and pulmonary embolism were seen. There were no treatment-related deaths. The drug's prescribing information includes warnings and precautions for hypersensitivity, QTc interval prolongation, and embryo-fetal toxicity, according to the FDA statement. A phase 3 trial is underway to confirm the benefit of dordaviprone for recurrent H3 K27M-mutant diffuse glioma. M. Alexander Otto is a physician assistant with a master's degree in medical science and a journalism degree from Newhouse. He is an award-winning medical journalist who worked for several major news outlets before joining Medscape. Alex is also an MIT Knight Science Journalism fellow. Email: aotto@
